All eyes turn to NVDA on Wednesday. The $5.4 trillion AI chipmaker reports after the close. Expectations are sky-high. Leveraged NVDA ETFs are flashing stress signals ahead of results. NVDL utilization hit 100% for six straight sessions. Short interest in the bearish NVDG ETF soared 49% in a week to 47.6% of float. Markets are clearly positioning hard into the print.
TSLA faces fresh scrutiny today. Two robotaxi crashes in Austin have put pressure on the EV maker. Elon Musk, speaking in Tel Aviv, claimed self-driving will cover 90% of distance within a decade. The gap between bold claims and on-road reality is widening for bears to exploit.
Ryanair delivered a standout result. Full-year profit after tax jumped 40% to €2.26B. Revenue rose 11% to €15.54B. Fares climbed 10% as 208 million passengers flew the airline. The result underlines strong European travel demand.
AstraZeneca scored an FDA approval today. Its Baxfendy drug — a first-in-class treatment for uncontrolled hypertension — cleared the regulator. GSK also won approval in Japan for its Arexvy RSV vaccine in a broader patient group. European pharma is having a strong Monday.
Philips caught attention too. Its cost to borrow surged 268% in a week to 24.05%. The Dutch firm also won a major Stockholm hospital-at-home contract covering 15,000 patients annually.
Beyond NVDA, HD and PGR report Tuesday. LOW and TGT follow Wednesday. Consumer spending readings will be closely watched alongside the AI mega-print.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
